Justin Smith
Stock Analyst at Bernstein
(4.37)
# 1,201
Out of 4,408 analysts
163
Total ratings
69.6%
Success rate
11.4%
Average return
Main Sectors:
Stocks Rated by Justin Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: GSK GSK plc | Rated: Buy | 2,630p | $1,958.00 | +34.32% | 22 | Jun 9, 2026 | |
| LON: AZN AstraZeneca PLC | Maintained: Buy | 18,600p | $13,200.00 | +40.91% | 31 | Jun 5, 2026 | |
| LON: 0QW0 argenx SE | Maintained: Buy | €915.00 → €877.00 | $757.80 | +15.73% | 11 | May 12, 2026 | |
| LON: 0QIU Novo Nordisk A/S | Maintained: Sell | kr 175.00 | $287.70 | -39.17% | 2 | May 6, 2026 | |
| SWX: NOVN Novartis AG | Rated: Hold | CHF 125.00 | $120.22 | +3.98% | 1 | Apr 29, 2026 | |
| EPA: SAN Sanofi | Maintained: Buy | €110.00 → €107.00 | $75.54 | +41.65% | 2 | Apr 28, 2026 | |
| SWX: ROP Roche Holding AG | Rated: Buy | CHF 395.00 | $326.10 | +21.13% | 24 | Apr 27, 2026 | |
| NVS Novartis AG | Initiated Coverage: Hold | n/a | $151.56 | - | 1 | Mar 19, 2026 | |
| ETR: MRK Merck KGaA | Initiated Coverage: Hold | €112.00 | $132.70 | -15.60% | 1 | Mar 18, 2026 | |
| LON: 0MGB Genmab A/S | Maintained: Sell | kr 1,015 → kr 1,400 | $1,616.00 | -13.37% | 9 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | n/a | $24.58 | - | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $26.00 | - | 8 | Aug 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | €10.50 → €2.90 | $1.25 | n/a | 3 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €22.00 → €21.50 | $9.09 | n/a | 2 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $85 → $51 | $56.24 | n/a | 10 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | $104 | $114.90 | n/a | 4 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | CHF 965.00 → CHF 544.00 | $495.00 | n/a | 8 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | €45.80 → €71.00 | $40.70 | n/a | 7 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €69.00 → €70.00 | $38.85 | n/a | 6 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $51.01 | n/a | 2 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $172 → $140 | $221.59 | n/a | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $52.23 | n/a | 1 | Sep 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $11.27 | n/a | 1 | Nov 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $23.45 | n/a | 1 | Feb 24, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $78 | $1,129.35 | n/a | 1 | Apr 7, 2016 |
GSK plc
Jun 9, 2026
Rated: Buy
Price Target: 2,630p
Current: $1,958.00
Upside: +34.32%
AstraZeneca PLC
Jun 5, 2026
Maintained: Buy
Price Target: 18,600p
Current: $13,200.00
Upside: +40.91%
argenx SE
May 12, 2026
Maintained: Buy
Price Target: €915.00 → €877.00
Current: $757.80
Upside: +15.73%
Novo Nordisk A/S
May 6, 2026
Maintained: Sell
Price Target: kr 175.00
Current: $287.70
Upside: -39.17%
Novartis AG
Apr 29, 2026
Rated: Hold
Price Target: CHF 125.00
Current: $120.22
Upside: +3.98%
Sanofi
Apr 28, 2026
Maintained: Buy
Price Target: €110.00 → €107.00
Current: $75.54
Upside: +41.65%
Roche Holding AG
Apr 27, 2026
Rated: Buy
Price Target: CHF 395.00
Current: $326.10
Upside: +21.13%
Novartis AG
Mar 19, 2026
Initiated Coverage: Hold
Price Target: n/a
Current: $151.56
Upside: -
Merck KGaA
Mar 18, 2026
Initiated Coverage: Hold
Price Target: €112.00
Current: $132.70
Upside: -15.60%
Genmab A/S
Feb 23, 2026
Maintained: Sell
Price Target: kr 1,015 → kr 1,400
Current: $1,616.00
Upside: -13.37%
Sep 8, 2025
Reiterated: Sell
Price Target: n/a
Current: $24.58
Upside: -
Aug 17, 2025
Maintained: Hold
Price Target: n/a
Current: $26.00
Upside: -
Mar 31, 2025
Downgraded: Hold
Price Target: €10.50 → €2.90
Current: $1.25
Upside: n/a
Dec 10, 2024
Maintained: Buy
Price Target: €22.00 → €21.50
Current: $9.09
Upside: n/a
Mar 11, 2024
Downgraded: Hold
Price Target: $85 → $51
Current: $56.24
Upside: n/a
Mar 11, 2024
Downgraded: Sell
Price Target: $104
Current: $114.90
Upside: n/a
Dec 13, 2023
Maintained: Buy
Price Target: CHF 965.00 → CHF 544.00
Current: $495.00
Upside: n/a
Nov 17, 2023
Upgraded: Buy
Price Target: €45.80 → €71.00
Current: $40.70
Upside: n/a
Nov 17, 2023
Maintained: Buy
Price Target: €69.00 → €70.00
Current: $38.85
Upside: n/a
Feb 27, 2023
Upgraded: Buy
Price Target: n/a
Current: $51.01
Upside: n/a
Nov 8, 2022
Downgraded: Hold
Price Target: $172 → $140
Current: $221.59
Upside: n/a
Sep 3, 2019
Upgraded: Buy
Price Target: n/a
Current: $52.23
Upside: n/a
Nov 12, 2018
Maintained: Buy
Price Target: n/a
Current: $11.27
Upside: n/a
Feb 24, 2017
Downgraded: Hold
Price Target: n/a
Current: $23.45
Upside: n/a
Apr 7, 2016
Initiated Coverage: Hold
Price Target: $78
Current: $1,129.35
Upside: n/a